Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-driven Cancers
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Uniquely Blocks News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Uniquely Blocks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Uniquely Blocks Today - Breaking & Trending Today
Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-driven Precision Medicine to Accelerate Clinical Development of HMBD-001 In HER3 Driven Cancers
Share this article Share this article SINGAPORE, Dec. 14, 2020 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to drive the development of Hummingbird's lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 (NRG1) fusions. As part of the collaboration, Hummingbird will be leveraging Tempus' AI-enabled pl...
Source: prnewswire.com